Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Amgen in $1.9bn swoop for Five Prime and its gastric cancer drugAmgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer Share XAmgen in $1.9bn swoop for Five Prime and its gastric cancer drughttps://pharmaphorum.com/news/amgen-in-1-9bn-swoop-for-five-prime-and-its-gastric-cancer-drug/
AZ trumpets tezepelumab data as filing for severe asthma loomsAstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to Share XAZ trumpets tezepelumab data as filing for severe asthma loomshttps://pharmaphorum.com/news/az-trumpets-tezepelumab-data-as-filing-for-severe-asthma-looms/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
Amgen hands off leprosy, TB candidate to Australian non-profitAmgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Share XAmgen hands off leprosy, TB candidate to Australian non-profithttps://pharmaphorum.com/news/amgen-hands-off-leprosy-tb-candidate-to-australian-non-profit/
AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialAstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a Share XAZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialhttps://pharmaphorum.com/news/az-amgens-asthma-hope-tezepelumab-flunks-phase-3-trial/
Amgen files KRAS trailblazer sotorasib with FDA for lung cancerAmgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer Share XAmgen files KRAS trailblazer sotorasib with FDA for lung cancerhttps://pharmaphorum.com/news/amgen-files-kras-inhibitor-with-fda/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
